Matteo Lambertini, Associate Professor at the University of Genova, shared a post on X:
“Presented at ESMO25 and simultaneously published in Annals of Oncology, the updated data from monarchE showing overall survival benefit with addition of abemaciclib to endocrine therapy in high-risk HR+/HER2- Breast Cancer.”
Follow the latest ESMO 2025 news on OncoDaily.
